Eupalinolide B是一种从Eupatorium lindleyanum中分离的具有多种生物学活性的胚芽倍半萜类化合物。
Cas No.:877822-41-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Eupalinolide B is a germacrane sesquiterpene lactone isolated from Eupatorium lindleyanum that possesses a variety of biological activities[1-2]. Eupalinolide B induces cell apoptosis and autophagy. Eupalinolide B can be used in research related to various cancers, neurodegenerative diseases, and other conditions[3-4].
In vitro, Eupalinolide B was used to treat human hepatoma cell lines SMMC-7721 and HCCLM3 (6, 12, 24μM) for 48 hours. Eupalinolide B significantly inhibited cell proliferation by arresting the cell cycle in the S phase and induced ferroptosis mediated by endoplasmic reticulum stress and HO-1 activation[5]. Eupalinolide B (4–8μM) was used to treat RAW264.7 cells stimulated with Pg-LPS (10μg/mL) for 24 hours. Eupalinolide B significantly inhibited the expression and secretion of pro-inflammatory factors (TNF-α, IL-6, IL-1β) and suppressed IκBα phosphorylation and the activation/nuclear translocation of NF-κB p65[6].
In vivo, Eupalinolide B (20mg/kg or 40mg/kg) was administered daily via intraperitoneal injection to nude mice bearing PANC-1 pancreatic cancer cell xenografts for 4 weeks. Eupalinolide B significantly slowed tumor growth, resulting in markedly reduced tumor volume and weight[7]. Eupalinolide B (20mg/kg) was administered daily via intraperitoneal injection to a BALB/c nude mouse xenograft model bearing KRAS-mutant H358 cells for 18 days. Eupalinolide B significantly inhibited tumor growth, leading to a clear reduction in both tumor volume and weight[8].
References:
[1] Gu SL, Liu XS, Xu ZS, et al. Eupalinolide B alleviates rheumatoid arthritis through the promotion of apoptosis and autophagy via regulating the AMPK/mTOR/ULK-1 signaling axis. Int Immunopharmacol. 2025 Feb 20;148:114179.
[2] Yang L, Chen H, Hu Q, et al. Eupalinolide B attenuates lipopolysaccharide-induced acute lung injury through inhibition of NF-κB and MAPKs signaling by targeting TAK1 protein. Int Immunopharmacol. 2022 Oct;111:109148.
[3] Wang TT, Zhou MY, Gong XN, et al. Eupalinolide B alleviates corticosterone-induced PC12 cell injury and improves depression-like behaviors in CUMS rats by regulating the GSK-3β/β-catenin pathway. Biochem Pharmacol. 2025 May;235:116831.
[4] Bai Q, Wang C, Ding N, et al. Eupalinolide B targets DEK and PANoptosis through E3 ubiquitin ligases RNF149 and RNF170 to negatively regulate asthma. Phytomedicine. 2025 Jun;141:156657.
[5] Zhang Y, Zhang H, Mu J, et al. Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway. Acta Biochim Biophys Sin (Shanghai). 2022 Jul 25;54(7):974-986.
[6] Kuang W, Zhuge R, Song P, et al. Eupalinolide B inhibits periodontitis development by targeting ubiquitin conjugating enzyme UBE2D3. MedComm (2020). 2025 Jan 14;6(1):e70034.
[7] Huang Q, Yang J, Zhang J, et al. Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. iScience. 2024 Jul 14;27(8):110496.
[8] Wang W, Yu J, Huang T, et al. Eupalinolide B exerts cytotoxic effects against KRAS-mutant NSCLC through Nrf2/HO-1-regulated ferroptosis. Acta Biochim Biophys Sin (Shanghai). 2025 Dec 4.
Eupalinolide B是一种从Eupatorium lindleyanum中分离的具有多种生物学活性的胚芽倍半萜类化合物[1-2]。Eupalinolide B可引起细胞凋亡、自噬。Eupalinolide B可被用于多种癌症、神经退行性疾病等的相关研究[3-4]。
在体外，Eupalinolide B处理人肝癌细胞系SMMC-7721和HCCLM3（6、12、24μM）48小时。Eupalinolide B通过将细胞周期阻滞在S期来显著抑制细胞增殖，并引起内质网应激和HO-1激活介导诱导铁死亡[5]。Eupalinolide B（4–8μM）处理经Pg-LPS（10μg/mL）刺激的RAW264.7细胞24小时。Eupalinolide B显著抑制促炎因子（TNF-α、IL-6、IL-1β）的表达和分泌，同时抑制IκBα磷酸化和NF-κB p65的激活与核转位[6]。
在体内，Eupalinolide B（20mg/kg或40mg/kg）每日腹腔注射于携带PANC-1胰腺癌细胞异种移植瘤的裸鼠4周。Eupalinolide B显著减慢了肿瘤生长，同时肿瘤体积和重量均明显减少[7]。Eupalinolide B（20mg/kg）每日腹腔注射于携带KRAS突变H358细胞的BALB/c裸鼠异种移植瘤模型18天。Eupalinolide B显著抑制了肿瘤生长，同时肿瘤体积和重量均明显减少[8]。
| Cell experiment [1]: | |
Cell lines | RAW264.7 murine macrophage cell line |
Preparation Method | RAW264.7 cells were stimulated with Porphyromonas gingivalis-lipopolysaccharide (Pg-LPS) (10μg/mL) and then treated with Eupalinolide B (4–8μM). |
Reaction Conditions | 4–8μM; 24h. |
Applications | Eupalinolide B (4–8μM) significantly inhibited the expression and secretion of pro-inflammatory factors (TNF-α, IL-6, IL-1β), and suppressed IκBα phosphorylation and NF-κB p65 activation/nuclear translocation in Pg-LPS-stimulated RAW264.7 cells. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice bearing KRAS-mutant H358 cell xenograft tumors |
Preparation Method | Mice were subcutaneously injected with H358 cells (5×10⁶) in serum-free medium into the right dorsum. The experimental group was then treated with Eupalinolide B (20mg/kg) via daily intraperitoneal injection for 18 days. Tumor volume and body weight were monitored. |
Dosage form | 20mg/kg; i.p.; once daily for 18 days. |
Applications | Eupalinolide B administration significantly inhibited tumor growth, resulting in reduced tumor volume and weight. Histopathological (H&E) analysis confirmed that Eupalinolide B markedly induced tumor cell damage. Eupalinolide B treatment increased the protein levels of Nrf2, HO-1, and ACSL4, while decreasing the levels of Keap1, GPX4, and FTH1 in tumor tissues, indicating the induction of ferroptosis in vivo. |
References: | |
| Cas No. | 877822-41-8 | SDF | |
| 别名 | 野马追内酯B | ||
| Canonical SMILES | O=C(O[C@@H]1C/C(COC(C)=O)=C/C[C@H](OC(C)=O)/C(C)=C/[C@@]([C@]1([H])C2=C)([H])OC2=O)/C(C)=C/CO | ||
| 分子式 | C24H30O9 | 分子量 | 462.49 |
| 溶解度 | Soluble in DMSO | 储存条件 | -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1622 mL | 10.811 mL | 21.6221 mL |
| 5 mM | 432.4 μL | 2.1622 mL | 4.3244 mL |
| 10 mM | 216.2 μL | 1.0811 mL | 2.1622 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet